Lixiu said it has commercialized SuoKang’s medical implants and surgical patch which are used to treat facial tissues defects and deformities to more than 1,400 medical institutions throughout China.

As part of the collaboration, Lixiu will also provide extensive clinical research for BIEL in China, where it has extensive patent coverage.

BIEL has also retained the services of Orian Healthcare to be its sales agent in the Middle East.

BIEL has also entered into a distribution agreement with India – based Juno Pharmaceuticals, which was formed by experienced Indian and Canadian private equity fund managers to focus on global opportunities for pharmaceuticals and medical devices.

BioElectronics president Andrew Whelan said the company is also presenting its products to retailers throughout both Western and Eastern Europe.